The authors focus on operational excellence in manufacturing of biotechnology therapeutic products in the QbD paradigm.
To investigate the best culture conditions, the authors used response surface methodology via Box-Behnken design.
To investigate the best culture conditions, the authors used response surface methodology via Box-Behnken design.
To investigate the best culture conditions, the authors used response surface methodology via Box-Behnken design.
The development of mAb formulations poses challenges at the manufacturing, stability, analytical, and administration levels.
This article demonstrates that a modified SDS–PAGE can be easily used as a tool for quantifying the degree of protein degradation.
This article demonstrates that a modified SDS–PAGE can be easily used as a tool for quantifying the degree of protein degradation.
The increased use of single-use bags in biologic manufacturing poses the risk of pinholes and other defects that cannot currently be tested for.
The increased use of single-use bags in biologic manufacturing poses the risk of pinholes and other defects that cannot currently be tested for.
This article demonstrates that a modified SDS–PAGE can be easily used as a tool for quantifying the degree of protein degradation.
The increased use of single-use bags in biologic manufacturing poses the risk of pinholes and other defects that cannot currently be tested for.
Webinar Date/Time: Wed, Feb 26, 2025 11:00 AM EST
Pharmaceutical Technology® Group spoke with Erik Wiklund, CEO of Circio, about the impact of the post-COVID-19 world on the pharmaceutical industry and how that has shifted the talent pool.
The companies have restructured their existing collaboration into a licensing agreement that invests in mRNA development.
As recent COVID-19 vaccine facility citations make clear, failure to meet cleaning and sanitization requirements puts patients, facilities, and operators at risk.
As politicians focus on drug cost reduction, biopharmaceutical companies in the US are moving to states with lower taxes, and relocating some facilities that had been offshore.
Andrew Bulpin, head of Process Solutions, MilliporeSigma, shares insights on characterizing CQAs in biopharmaceutical development and the different tests that should be carried out when assessing an investigational drug.
Reliably detecting low amounts of high molecular weight impurities during process development and characterization of biopharmaceutical products.
Packaging and packaging line innovations are addressing the industry’s growing use of biologics.
Advances in fill/finish for parenteral packaging address demands for efficiency and product safety.
Emergence of advanced manufacturing technology to ensure quality of biopharmaceutical drugs combined with efforts to identify a regulatory pathway indicate that a distributed manufacturing model is within reach.
Freezers, shipping containers, and tracking systems aid distribution of COVID-19 vaccines.
A series of advancements has changed the way bioprocesses are developed and optimized.
A consistent approach in assessing risk is an important aspect of successful quality management.
Webinar Date/Time: Thursday, December 5th, 2024 at 11:00 AM EST
What will manufacturers have to do to ensure the continued uptake of biosimilars?
This report describes the first known attempt at quantifying the success of such processes in inducing nucleation on a 56–m2 freeze dryer operating at a load of 195,960 vials.
This report describes the first known attempt at quantifying the success of such processes in inducing nucleation on a 56–m2 freeze dryer operating at a load of 195,960 vials.
This report describes the first known attempt at quantifying the success of such processes in inducing nucleation on a 56–m2 freeze dryer operating at a load of 195,960 vials.